Drug Profile
Research programme: HIV/AIDS therapeutics - Fox Chase Chemical Diversity Center/ University of Pennsylvania
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Fox Chase Chemical Diversity Center; University of Pennsylvania
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 04 Jul 2016 Preclinical trials in HIV-1 infections in USA (unspecified route)